Pilot Study to Evaluate the Oral Absorption, Safety, and Tolerability of Nepadutant Administered as Single Oral Doses to Infants With Colic and Other Functional Gastrointestinal Disorders
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
- 试验地点
- 3
- 主要终点
- Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.
研究概览
简要总结
The purpose of the study is to evaluate the gastrointestinal absorption of nepadutant after single dose as oral solution (and the effect of age on its oral absorption) in infants. Oral absorption is evaluated through the drug recovery in urine.
详细描述
This trial aims to evaluate the oral adsorption of nepadutant (0.1 or 0.5 mg/Kg given as one single dose as oral solution) in infants divided in three age strata (from 6 to 24 weeks old). Oral absorption is evaluated by measuring the amount of nepadutant in the urine output collected during the 24 hours after oral administration with special diapers.
Safety and tolerability of the drug will be evaluated by monitoring any changes in signs/symptoms at medical examination and vital signs during the fist 4 hours post-dose in the Hospital site and then by the parents at home up to 24 hours and 1 week post nepadutant administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Weeks 至 24 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will be eligible for inclusion in the study if they meet all of the following criteria:
- •Infants with a history consistent with a diagnosis of colic or other functional gastrointestinal disorders
- •Age >6 weeks and < 24 weeks
- •At least 44 weeks post-conceptual age at enrolment
- •Normal growth
- •Informed consent by parents (one or both) or legal guardian
- •Caregiver available to be trained in collection and storage of used diapers
- •Caregiver available to record feeding episodes and defecations on the diary
排除标准
- •Subjects will be excluded from the study if they meet any of the following criteria:
- •Clinical evidence of major cardiovascular, respiratory, renal, hepatic, endocrine, metabolic, gastrointestinal (excluding infantile colic and other functional gastrointestinal disorders, unless associated to symptoms which are likely to interfere with drug absorption, e.g. frequent vomiting), haematological, severe dermatological or neurological pathology or other diseases;
- •Previous major surgery or blood loss
- •Intake of antimuscarinic drugs, simethicone, or dimethicone 24 hours before study treatment administration.
研究组 & 干预措施
1
Nepadutant 0.1 mg/kg
干预措施: Nepadutant (Drug)
2
Nepadutant 0.5 mg/kg
干预措施: Nepadutant (Drug)
结局指标
主要结局
Drug Concentration Measurement in the Urine Collected by Diapers Along 24 Hours Post Dose and One Week After Dose in All Treated Infants and by Age and Dose Subgroups.
时间窗: 24 hours
Nepadutant was measured in the 24-h urine collection post both doses (0.1 and 0.5 mg/kg dose), in the age stratum 18-24 weeks, using urinary collection/extraction from pre-weighed special fiber based diapers.
次要结局
- Number of Adverse Events After Administration of Single Oral Doses up to 0.5 mg/kg of Nepadutant in Infants.(one week)